Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M165,841Revenue $M41,398Net Margin (%)27.0Altman Z-Score3.3
Enterprise Value $M180,626EPS $3.9Operating Margin %12.5Piotroski F-Score4
P/E(ttm)15.2Beneish M-Score-2.9Pre-tax Margin (%)40.0Higher ROA y-yY
Price/Book3.510-y EBITDA Growth Rate %5.4Quick Ratio1.3Cash flow > EarningsN
Price/Sales4.15-y EBITDA Growth Rate %4.0Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow31.3y-y EBITDA Growth Rate %75.5ROA % (ttm)10.9Higher Current Ratio y-yN
Dividend Yield %3.1PEG3.8ROE % (ttm)23.3Less Shares Outstanding y-yY
Payout Ratio %46.0Shares Outstanding M2,825ROIC % (ttm)6.5Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKVanguard Health Care Fund 2015-06-30 Add0.65%$56.73 - $60.89
($58.76)
$ 58.70-0%Add 14.09%45,748,498
MRKKahn Brothers 2015-06-30 Reduce-0.13%$56.73 - $60.89
($58.76)
$ 58.70-0%Reduce 1.28%1,016,613
MRKKen Fisher 2015-06-30 Add0.02%$56.73 - $60.89
($58.76)
$ 58.70-0%Add 2.35%6,836,547
MRKVanguard Health Care Fund 2015-03-31 Add0.53%$56.06 - $63.03
($59.34)
$ 58.70-1%Add 12.04%40,096,948
MRKDodge & Cox 2015-03-31 Reduce-0.44%$56.06 - $63.03
($59.34)
$ 58.70-1%Reduce 24.30%25,448,977
MRKKahn Brothers 2015-03-31 Reduce-0.22%$56.06 - $63.03
($59.34)
$ 58.70-1%Reduce 2.18%1,029,815
MRKJoel Greenblatt 2015-03-31 Reduce-0.17%$56.06 - $63.03
($59.34)
$ 58.70-1%Reduce 35.28%676,758
MRKJames Barrow 2015-03-31 Add0.13%$56.06 - $63.03
($59.34)
$ 58.70-1%Add 7.03%24,464,116
MRKCharles Brandes 2015-03-31 Reduce-0.07%$56.06 - $63.03
($59.34)
$ 58.70-1%Reduce 3.69%2,221,791
MRKNWQ Managers 2015-03-31 Reduce-0.01%$56.06 - $63.03
($59.34)
$ 58.70-1%Reduce 9.00%76,286
MRKMario Gabelli 2015-03-31 Add0.01%$56.06 - $63.03
($59.34)
$ 58.70-1%Add 11.45%160,943
MRKKen Fisher 2015-03-31 Add$56.06 - $63.03
($59.34)
$ 58.70-1%Add 0.59%6,679,499
MRKKahn Brothers 2014-12-31 Reduce-0.54%$53.43 - $61.88
($58.42)
$ 58.700%Reduce 5.08%1,052,807
MRKVanguard Health Care Fund 2014-12-31 Add0.32%$53.43 - $61.88
($58.42)
$ 58.700%Add 7.08%35,788,048
MRKJoel Greenblatt 2014-12-31 Add0.23%$53.43 - $61.88
($58.42)
$ 58.700%Add 94.88%1,045,652
MRKFirst Eagle Investment 2014-12-31 Reduce-0.16%$53.43 - $61.88
($58.42)
$ 58.700%Reduce 99.16%9,050
MRKJoel Greenblatt 2014-09-30 Add0.24%$55.64 - $61.18
($58.89)
$ 58.70-0%Add 323.00%536,550
MRKFirst Eagle Investment 2014-09-30 Reduce-0.1%$55.64 - $61.18
($58.89)
$ 58.70-0%Reduce 38.25%1,083,826
MRKKahn Brothers 2014-09-30 Reduce-0.09%$55.64 - $61.18
($58.85)
$ 58.70-0%Reduce 0.97%1,109,189
MRKCharles Brandes 2014-09-30 Reduce-0.08%$55.64 - $61.18
($58.85)
$ 58.70-0%Reduce 4.69%2,320,288
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schechter Adam HEVP & Pres-Global Human Health 2015-05-11Sell10,634$60.44-2.3view
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy 2015-05-08Sell38,368$60.99-3.18view
Kuhlik Bruce NExe V-P & Gen Counsel 2015-05-04Sell56,064$60.2-1.91view
Holston Michael JEVP, Legal 2015-04-29Sell95,624$59.84-1.32view
Kuhlik Bruce NExe V-P & Gen Counsel 2015-04-29Sell156,902$59.82-1.29view
FRAZIER KENNETH CChairman, President & CEO 2015-02-18Sell5,164$58.670.65view
Deese Willie AExe V-P & Pres. MMD 2015-02-11Sell135,864$58.560.84view
WENDELL PETER CDirector 2015-02-09Sell5,000$58.760.49view
Schechter Adam HEVP & Pres-Global Human Health 2015-01-15Sell74,200$62.48-5.49view
FRAZIER KENNETH CChairman, President & CEO 2015-01-09Sell8,840$62.47-5.47view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

    News about MRK:

    Articles On GuruFocus.com
    Merck Reports Strong Second Quarter 2015 Earnings with Improved Outlook for the Full Year Jul 31 2015 
    Manning & Napier Advisors' Most Weighted Trades in Q2 2015 Jul 10 2015 
    Intrexon Corp is expanding his business Jun 25 2015 
    Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Abbvie Inc. Dividend Stock Analysis May 26 2015 
    Endo International Acquires Par Pharmaceuticals For $8 Billion May 21 2015 
    Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
    Vanguard Adds to Four of Its Largest Stakes May 04 2015 
    Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 

    More From Other Websites
    Madison Street Partners Reshuffles Its Portfolio and Bets on ETFs; See Its Top Stock Picks Aug 03 2015
    Positive Developments Around Ebola Aug 03 2015
    Merck and Nano-C Present Enhanced Materials for Organic Photovoltaics Aug 03 2015
    Merck Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry... Aug 03 2015
    Guinea Plans Ebola Inoculation Campaign After Vaccine Success Aug 01 2015
    Guinea Plans Ebola Inoculation Campaign Aug 01 2015
    WHO Says Ebola Vaccine Effective in African Trial Jul 31 2015
    Ebola game changer? Jul 31 2015
    There's more to Merck's Ebola vaccine than money Jul 31 2015
    Experimental Ebola vaccine could stop virus in West Africa Jul 31 2015
    Experimental Ebola vaccine could stop virus in West Africa Jul 31 2015
    Merck: Study shows potential Ebola vaccine has '100 percent efficacy' Jul 31 2015
    ​Merck should follow GSK’s lead and commit to selling its potential Ebola vaccine at cost Jul 31 2015
    Dow 30 Stock Roundup: Pfizer, P&G, Merck Beat on Earnings, DuPont Misses Estimates - Analyst Blog Jul 31 2015
    Merck's Ebola Vaccine Found to Be Effective by Expert Panel Jul 31 2015
    After Merck success, work goes on with other Ebola vaccines Jul 31 2015
    After Merck success, work goes on with other Ebola vaccines Jul 31 2015
    CNBC update: Ebola vaccine Jul 31 2015
    THLD: Update on 2Q15 Financials Jul 31 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK